The Phase 1b trial aimed to optimize the dosing of rinzimetostat, and the results indicate that the combination therapy could lead to improved progression-free survival (PFS) rates compared to existing therapies. Specifically, the report mentions that the combination therapy has demonstrated a favorable safety profile, with a lower frequency of adverse events compared to other treatments in the same category. This is particularly important for patients who often experience significant side effects from cancer therapies.
The company has attached a presentation as Exhibit 99.1 to the filing, which contains detailed data from the trial, including the preliminary profile of the Phase 3 dose and the next steps in the clinical development of rinzimetostat. ORIC Pharmaceuticals is planning to initiate a global Phase 3 trial in the first half of 2026, which will further evaluate the efficacy of rinzimetostat in combination with darolutamide in a larger patient population.
This update is expected to have a small positive effect on ORIC's stock price as it reflects the company's progress in developing a potentially effective treatment for a significant unmet medical need in prostate cancer. Investors may view this as a step forward in ORIC's clinical pipeline, particularly given the competitive landscape of prostate cancer therapies. The company continues to evaluate rinzimetostat's potential in other solid tumors, which could further enhance its market position and investor interest.
